Agenda & Faculty, March 8-9 2024
08:00
Registration opens
08:50
Opening introduction to the meeting, Ryan Fitzpatrick, CEO, MD Education
09:00
Keynote Speaker; Utility of ctDNA in CART and bispecific therapy
Brian Sworder, MD - UC Irvine, California
Session I: Leukemia Part 1
09:30
Tisa-cel in pediatric B-ALL. Current and future plans
Steve Grupp, MD – University of Pennsylvania, Pennsylvania
09:50
Brexu-cel in adults B-ALL. Current and future plans
Nitin Jain, MD – MD Anderson Cancer Center, Houston, Texas
10:10
CD22 CAR-T’s - Promise and Perils
Rebecca Gardner, MD - St Jude Cancer Center, Memphis, Tennessee
10:30
Panel Discussion
10:50
Coffee Break
Session II: Leukemia Part 2
11:10
Role of Bispecifics (CD19, CD20) in B-ALL
Elias Jabbour, MD – MD Anderson Cancer Center, Houston, Texas
11:30
Incorporating CAR-T in current management of Adult ALL
Anjali Advani, MD – Cleveland Clinic, Ohio
11:50
CAR-T in CLL
Catherine Coombs, MD - UC Irvine, California
12:10
Panel Discussion
12:30
Case Presentation
Nitin Jain, MD – MD Anderson Cancer Center, Houston, Texas
13:00
Lunch Break
Session III: Emerging Concepts Part 1
13:50
CD22 CAR
David Miklos, MD – Stanford University, California
14:10
Mechanisms Affecting Allogeneic CAR-T Cell Expansion and Rejection
Andrew Jallouk, MD – Vanderbilt University Medical Center, Nashville, Tennessee
14:30
Panel Discussion
14:50
Coffee Break
Session IV: Emerging Concepts Part 2
15:10
CAR-T for T-cell neoplasms
Maksim Mamonkin, MD – Baylor College of Medicine, Houston, Texas
15:30
Emerging Bispecifics
Amrita Krishnan, MD – City of Hope, California
15:50
Mechanisms of CAR Resistance and novel targets with MM
Noopur Raje, MD – Massachusetts General Hospital, Boston, Massachusetts
16:10
Panel Discussion
16:30
Adjourn
09:00
Keynote Speaker; Value of real-world studies/outcomes researchL
Chris Flowers, MD – MD Anderson Cancer Center, Houston, Texas
Session V: Lymphoma Part 1
09:30
CD19 CAR-T in LBCL
Matthew Lunning, MD - University of Nebraska, Nebraska
09:50
CD20 Bispecifics in LBCL
Elizabeth Budde, MD – City of Hope, California
10:10
CD19 CAR-T in MCL
Bijal Shah, MD – Moffitt Cancer Center, Florida
10:30
Panel Discussion
10:50
Coffee Break
Session VI: Lymphoma Part 2
11:10
CD19 CAR-T in indolent NHL
Reem Karmali, MD - Northwestern University, Illinois
11:30
CD20 Bispecifics in MCL and NHL,
Krish Patel, MD Swedish Cancer Institute, Seattle, Washington
11:50
Bispecifics vs CAR-T in NHL,
Justin Kline, MD – University of Chicago, Illinois
12:10
Panel Discussion
12:30
Case Presentation
Sattva Neelapu, MD – MD Anderson Cancer Center, Houston, Texa
12:50
Lunch Break
13:40
BMS Product Theatre
14:25
Keynote Speaker; Mechanism of Action and Resistance of Bispecifics
Nizar Bahlis, MD - University of Calgary, Canada
Session VII: Multiple Myeloma Part 1
14:55
Idecel in MM
Doris Hansen, MD - Moffitt Cancer Center, Florida
15:15
Ciltacel in MM
Tom Martin, MD – University of San Francisco, California
15:35
Approved Bispecifics in MM
Alexander Lesokhin, MD – Memorial Sloan Kettering Cancer Center, New York
15:55
Other BCMA CAR-T Cells in MM including Allogeneic CAR’s
Sham Mailankody, MD – Memorial Sloan Kettering Cancer Center, New York
16:15
Panel Discussion
16:35
Coffee Break
Session VIII: Multiple Myeloma Part 2
16:55
Early Line trials in MM,
Krina Patel, MD – MD Anderson Cancer Center, Houston, Texas
17:15
Practical considerations for incorporating CAR-T cells in MM
Surbhi Sidana, MD – Stanford Medical University, California
17:35
Novel CAR targets in MM
Yi Lin, MD – Mayo Clinic, Rochester, Minnesota
17:55
Panel Discussion
18:15
Case Presentation
Tom Martin, MD - University of San Francisco, California
